1
|
HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells. BIOMED RESEARCH INTERNATIONAL 2020; 2020:8610271. [PMID: 32596388 PMCID: PMC7273445 DOI: 10.1155/2020/8610271] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Revised: 03/18/2020] [Accepted: 04/10/2020] [Indexed: 12/16/2022]
Abstract
HMGN5 regulates biological function and molecular transcription via combining with a nucleosome. There has been growing evidence that aberrant expression of HMGN5 is associated with malignant neoplasm development and progression. In the present study, we found that the expression of HMGN5 is significantly higher in high-grade glioblastoma tissues than in low-grade samples. To clarify the function of HMGN5 in glioblastoma, we knocked down HMGN5 in U87 and U251 glioblastoma cells via siRNA. The results demonstrated that HMGN5 was involved in the regulation of proliferation and apoptosis, migration, and invasion of glioblastoma cells. These outcomes also indicated that silencing HMGN5 possibly suppressed the expression of p-AKT and p-ERK1/2. Taken together, our research reveals that HMGN5 might be an efficient target for glioblastoma-targeted therapy.
Collapse
|
2
|
Ehlen L, Arndt J, Treue D, Bischoff P, Loch FN, Hahn EM, Kotsch K, Klauschen F, Beyer K, Margonis GA, Kreis ME, Kamphues C. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. BMC Cancer 2020; 20:417. [PMID: 32404074 PMCID: PMC7222463 DOI: 10.1186/s12885-020-06929-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Accepted: 05/05/2020] [Indexed: 01/05/2023] Open
Abstract
Background Pancreatic cancer remains a fatal disease. Experimental systems are needed for personalized treatment strategies, drug testing and to further understand tumor biology. Cell cultures can serve as an excellent preclinical platform, but their generation remains challenging. Methods Tumor cells from surgically removed pancreatic ductal adenocarcinoma (PDAC) specimens were cultured under novel protocols. Cellular growth and composition were analyzed and culture conditions were continuously optimized. Characterization of cell cultures and primary tumors was performed via hematoxylin and eosin (HE) and immunofluorescence (IF) staining. Results Protocols for two- and three-dimensional PDAC primary cell cultures could successfully be established. Primary cell culture depended on dissociation techniques, growth factor supplementation and extracellular matrix components containing Matrigel being crucial for the transformation to three-dimensional PDAC organoids. The generated cultures showed to be highly resemblant to established PDAC primary cell cultures. HE and IF staining for cell culture and corresponding primary tumor characterization could successfully be performed. Conclusions The work presented herein shows novel and effective methods to successfully establish primary PDAC cell cultures in a distinct time frame. Factors contributing to cell growth and differentiation could be identified with important implications for further primary cell culture protocols. The established protocols might serve as novel tools in personalized tumor therapy.
Collapse
Affiliation(s)
- L Ehlen
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.
| | - J Arndt
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - D Treue
- Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - P Bischoff
- Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - F N Loch
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - E M Hahn
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - K Kotsch
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - F Klauschen
- Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - K Beyer
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - G A Margonis
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, USA
| | - M E Kreis
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - C Kamphues
- Department of General, Visceral and Vascular Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
3
|
Monkman JH, Thompson EW, Nagaraj SH. Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. Cancers (Basel) 2019; 11:E1745. [PMID: 31703358 PMCID: PMC6896204 DOI: 10.3390/cancers11111745] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 10/30/2019] [Accepted: 10/30/2019] [Indexed: 12/13/2022] Open
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is a particularly insidious and aggressive disease that causes significant mortality worldwide. The direct correlation between PDAC incidence, disease progression, and mortality highlights the critical need to understand the mechanisms by which PDAC cells rapidly progress to drive metastatic disease in order to identify actionable vulnerabilities. One such proposed vulnerability is epithelial mesenchymal plasticity (EMP), a process whereby neoplastic epithelial cells delaminate from their neighbours, either collectively or individually, allowing for their subsequent invasion into host tissue. This disruption of tissue homeostasis, particularly in PDAC, further promotes cellular transformation by inducing inflammatory interactions with the stromal compartment, which in turn contributes to intratumoural heterogeneity. This review describes the role of EMP in PDAC, and the preclinical target discovery that has been conducted to identify the molecular regulators and effectors of this EMP program. While inhibition of individual targets may provide therapeutic insights, a single 'master-key' remains elusive, making their collective interactions of greater importance in controlling the behaviours' of heterogeneous tumour cell populations. Much work has been undertaken to understand key transcriptional programs that drive EMP in certain contexts, however, a collaborative appreciation for the subtle, context-dependent programs governing EMP regulation is needed in order to design therapeutic strategies to curb PDAC mortality.
Collapse
Affiliation(s)
- James H. Monkman
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia;
- School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4059, Australia
- Translational Research Institute, Brisbane, QLD 4102, Australia
| | - Erik W. Thompson
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia;
- School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4059, Australia
- Translational Research Institute, Brisbane, QLD 4102, Australia
| | - Shivashankar H. Nagaraj
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia;
- School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4059, Australia
- Translational Research Institute, Brisbane, QLD 4102, Australia
| |
Collapse
|
4
|
Liu L, Lang Z, Wang P, Wang H, Cao Y, Meng X, Hu J, Feng Y. The nucleosome binding protein 1 promotes the growth of gastric cancer cells. J Cancer 2019; 10:1132-1137. [PMID: 30854121 PMCID: PMC6400668 DOI: 10.7150/jca.29292] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 01/09/2019] [Indexed: 01/20/2023] Open
Abstract
Nucleosome binding protein 1 (NSBP1) is identified as a new member of HMGN family and is abnormally overexpressed in a variety of tumors. However, it remains unclear whether NSBP1 is overexpressed and promotes gastric cancer. In this study we employed RNAi mediated knockdown of NSBP1 to investigate potential oncogenic role of NSBP1 in gastric cancer. In BGC823 and SGC7901 gastric cancer cell lines, we showed that NSBP1 knockdown decreased cell proliferation while increased apoptosis in vitro. Western blot analysis showed that NSBP1 knockdown decreased the levels of anti-apoptotic protein Bcl-2 while increased the levels of pro-apoptotic protein Bax. In addition, NSBP1 knockdown inhibited the growth and increased the apoptosis of SGC7901 cells xenografted in nude mice. In conclusion, this study provides the first evidence that NSBP1 enhances the proliferation while inhibits the apoptosis of gastric cancer cells, and this is related to the regulation of the expression of apoptosis related proteins by NSBP1. These data suggest that NSBP1 plays oncogenic role in gastric cancer.
Collapse
Affiliation(s)
- Lantao Liu
- School of Basic Medicine, Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Zhifang Lang
- School of Basic Medicine, Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Pengyu Wang
- School of Basic Medicine, Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Hongwei Wang
- Department of Pathology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Yanli Cao
- School of Basic Medicine, Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Xianghui Meng
- Department of Dermatology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Jing Hu
- School of Basic Medicine, Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Yukuan Feng
- School of Basic Medicine, Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| |
Collapse
|